oldham
g
bridger
jc
effect
dexamethasoneinduc
immunosuppress
develop
faecal
antibodi
recoveri
resist
rotaviru
infect
vet
immunol
lmmunopathol
rotavirusna
rotavirusimmun
gnotobiot
calv
treat
high
dose
dexamethason
dx
suppress
immun
system
calv
infect
virul
rotaviru
inoculum
investig
role
immun
respons
recoveri
primari
rotaviru
infect
resist
secondari
rotaviru
infect
treatment
calv
dx
markedli
suppress
vitro
respons
peripher
blood
lymphocyt
mitogen
within
h
start
dx
treatment
suppress
similar
rotavirusna
rotavirusimmun
calv
contrast
effect
dx
treatment
specif
antibodi
respons
differ
depend
dx
treatment
start
relat
rotaviru
infect
dx
treatment
commenc
prior
primari
rotaviru
infect
system
local
specif
antibodi
respons
inhibit
calv
mitogen
antibodi
respons
suppress
exhibit
greater
clinic
sign
control
calv
infect
virul
rotaviru
viru
excret
affect
one
two
calv
dx
treatment
start
primari
rotaviru
infect
secondari
infect
system
local
antibodi
respons
primari
infect
challeng
infect
affect
calv
resist
challeng
virul
viru
dxuntreat
rotavirusimmun
calv
even
though
mitogen
respons
suppress
conclud
primari
rotaviru
infect
viru
excret
ceas
antibodi
mitogen
respons
suppress
resist
secondari
rotaviru
infect
occur
mitogen
respons
suppress
antibodi
level
normal
thu
evid
obtain
fulli
function
cellmedi
immun
mechan
essenti
resist
rotaviru
infect
evid
provid
abil
parenter
treatment
dx
suppress
mucos
well
system
antibodi
respons
follow
rotaviru
infect
system
local
immun
respons
stimul
includ
neutralis
nonneutralis
antibodi
van
zaan
et
al
saif
cellmedi
immun
kohl
et
al
totterdel
et
al
offit
dudzik
howev
unclear
immun
mechan
involv
either
resolut
primari
infect
resist
immun
anim
secondari
rotaviru
infect
studi
immunodefici
patient
chronic
rotaviru
excret
diarrhoea
saulsburi
et
al
wood
et
al
mice
sever
combin
immunodefici
diseas
scid
persist
excret
rotaviru
follow
experiment
infect
riepenhofftalti
et
al
indic
involv
immun
mechan
recoveri
primari
rotaviru
infect
howev
studi
tcelldefici
mice
demonstr
recoveri
rotaviru
infect
absenc
immun
respons
eiden
et
al
activ
immun
mechan
protect
gut
rotaviru
diseas
clearli
defin
one
mechan
thought
essenti
neutralis
antibodi
studi
experiment
anim
vaccin
studi
human
suggest
mechan
import
wood
et
al
bridger
oldham
clark
et
al
immun
system
cattl
consid
rel
resist
effect
ofglucocorticosteroid
gc
compar
mice
wilki
et
al
pruett
et
al
gc
treatment
nevertheless
mark
effect
bovin
immun
respons
review
roth
kaeberl
effect
includ
suppress
antibodi
cellmedi
immun
respons
howev
noth
known
effect
gc
intestin
antibodi
respons
paper
use
dxinduc
immunosuppress
tri
gain
understand
immun
mechan
involv
recoveri
primari
enter
infect
resist
secondari
enter
infect
addit
report
effect
dx
treatment
faecal
antibodi
respons
rotaviru
cattl
rotaviru
obtain
healthi
calf
passag
clone
cell
cultur
follow
serial
passag
four
gnotobiot
calv
bridger
pocock
pocock
challeng
rotaviru
inoculum
unclon
describ
previous
faecal
bridger
pocock
inocula
prepar
faecal
filtrat
gnotobiot
calv
deriv
rear
milkbas
diet
previous
describ
day
four
calv
age
day
infect
tcidso
ofrotaviru
day
four
calv
five
rotavirusna
calv
b
b
group
group
b
age
day
challeng
tcidso
virul
challeng
inoculum
daili
treatment
dexamethason
dx
mg
kg
bodi
weight
intervet
im
inject
start
calv
group
b
day
prior
challeng
infect
experiment
design
summaris
tabl
faecal
sampl
collect
daili
male
calv
daili
output
collect
aid
har
collect
bag
sera
obtain
everi
day
clinic
score
obtain
total
number
day
follow
clinic
sign
observ
chang
demeanour
anorexia
de
fine
failur
consum
food
within
min
offer
calv
normal
drank
within
min
faecal
output
greater
g
healthi
gnotobiot
calv
produc
g
day
chang
faecal
colour
light
yellow
brown
faecal
dri
matter
content
less
increas
pack
cell
volum
preinfect
level
rectal
temperatur
c
viru
detect
infect
assay
conduct
duplic
bridger
pocock
titr
express
logo
faec
ml
cultur
fluid
classspecif
elisa
use
measur
antibodi
rotaviru
group
antigen
serum
faec
previous
describ
bridger
oldham
except
isotypespecif
monoclon
antibodi
gener
gift
dr
naessen
ilrad
kenya
antiigm
igg
dr
c
stoke
bristol
vet
meal
school
uk
antiiga
use
place
polyclon
antisera
serum
assay
faecal
extract
igm
iga
assay
standard
includ
everi
assay
absorb
test
sampl
calcul
percentag
standard
result
shown
mean
duplic
assay
carri
differ
day
preliminari
studi
known
neg
sera
faecal
sampl
test
sampl
consid
posit
antibodi
titr
exceed
standard
serum
faecal
igm
serum
faecal
igg
serum
iga
faecal
iga
peripher
blood
mononuclear
cell
isol
centrifug
heparinis
blood
histopaqu
sigma
min
cell
interfac
wash
three
time
pb
resuspend
tissu
cultur
medium
concentr
cell
tissu
cultur
medium
use
gibco
supplement
foetal
calf
serum
fc
heat
inactiv
rain
flow
mmol
glutamin
iu
penicillin
mg
streptomycin
mmol
hepe
mmol
sodium
bicarbon
mononuclear
cell
prepar
ml
cell
cultur
flatbottom
micropl
nunclon
delta
nunc
without
addit
mitogen
optim
concentr
mitogen
phytohaemagglutinin
pha
concanavalin
cona
pokewe
mitogen
pwm
determin
previou
experi
ml
stock
respect
h
cultur
humidifi
atmospher
air
thymidin
tdr
ci
mmol
radiochem
centr
amersham
ad
well
h
cultur
cell
harvest
onto
glass
fibr
filter
semiautom
harvest
incorpor
tdr
cellular
dna
determin
liquid
scintil
count
follow
infect
untreat
rotavirusna
calv
group
j
inoculum
antibodi
respons
demonstr
serum
faec
three
calv
test
fig
tabl
serum
faecal
igm
respons
first
detect
day
inocul
reach
maximum
day
serum
respons
first
detect
day
serum
iga
respons
first
detect
day
two
three
calv
third
calf
show
serum
iga
respons
day
sampl
stop
faecal
iga
first
detect
day
two
three
calv
detect
faecal
respons
contrast
dx
treatment
rotavirusna
calv
group
b
suppress
delay
antibodi
respons
serum
faecal
igm
respons
detect
one
two
calv
test
calf
igm
respons
unusu
serum
igm
respons
peak
fall
control
anim
continu
rise
day
postinfect
reach
higher
titr
seen
control
calv
faecal
igm
antibodi
detect
day
short
live
serum
igg
iga
also
show
differ
kinet
delay
appear
obviou
igg
first
detect
day
postinfect
seen
low
level
even
follow
day
postinfec
follow
challeng
inoculum
day
fig
except
calf
b
suppress
serum
igm
respons
contrast
rotavirusna
calv
igg
antibodi
demonstr
faec
two
b
b
four
calv
day
challeng
infect
fig
circul
peripher
blood
lymphocyt
taken
cours
infect
fail
prolifer
cultur
vitro
rotaviru
antigen
data
shown
howev
immunosuppress
effect
dexamethason
cellmedi
immun
demonstr
cell
cultur
three
mitogen
mean
prolif
respons
pha
cona
pwm
day
period
dx
treatment
reduc
compar
respons
anim
period
dx
treatment
tabl
dexamethason
markedli
depress
mitogen
respons
treat
calv
h
commenc
treatment
although
mean
respons
three
mitogen
markedli
suppress
dx
treatment
respons
reappear
period
dxtreat
calv
fluctuat
seen
control
calv
repres
calv
group
c
shown
fig
g
level
seen
prior
infect
day
seen
untreat
calv
group
tabl
peak
viru
titr
calf
higher
untreat
calv
observ
viru
titr
tcidso
gi
record
previous
inoculum
dxuntreat
calv
bridger
pocock
second
calf
show
similar
viru
excret
pattern
untreat
calv
differ
dxtreat
untreat
calv
first
day
viru
detect
dxtreat
calv
sever
diseas
untreat
calv
clinic
score
dxtreat
anim
compar
untreat
calv
tabl
higher
clinic
score
mainli
due
increas
number
day
high
faecal
output
abnorm
faecal
colour
low
faecal
dri
matter
content
dxuntreat
calv
day
viru
excret
ceas
coincid
close
day
faecal
igm
antibodi
first
detect
tabl
howev
dxtreat
calv
faecal
antibodi
detect
day
iga
igm
postinfect
dexamethason
treatment
affect
clinic
outcom
challeng
dxtreat
group
untreat
group
c
rotavirusimmun
calv
resist
rotaviru
diseas
tabl
wherea
rotavirusna
calv
group
b
develop
diseas
tabl
howev
differ
viru
excret
two
rotavirusimmun
group
dxtreat
immun
calv
viru
excret
detect
challeng
tabl
surprisingli
untreat
immun
calv
excret
viru
similar
level
seen
naiv
calv
compar
tabl
group
c
even
though
show
clinic
sign
role
immun
system
recoveri
resist
rotaviru
infect
investig
suppress
immun
system
dx
recoveri
calv
primari
rotaviru
infect
affect
dx
treatment
although
calv
recov
durat
clinic
sign
increas
one
calf
viru
excret
prolong
find
agre
similar
studi
dx
treatment
reduc
resist
primari
infect
transmiss
gastroenter
viru
tgev
pig
shimizu
shimizu
respiratori
syncyti
viru
rsv
thoma
et
al
bovin
viral
diarrhoea
viru
bvdv
clark
et
al
calv
termin
viral
excret
coincid
appear
faecal
antibodi
dxuntreat
calv
dxtreat
calv
suggest
antibodymedi
mechan
essenti
termin
rotaviru
excret
may
import
clinic
recoveri
naiv
calv
rotaviru
infect
although
mitogen
respons
suppress
complet
ablat
howev
one
must
also
rais
caveat
dx
affect
varieti
immunolog
physiolog
process
measur
might
effect
recoveri
gut
infect
damag
mice
treatment
cortison
acet
induc
matur
enterocyt
make
resist
rotaviru
infect
wolf
et
al
appear
occur
studi
rotavirusna
dxtreat
calv
excret
similar
level
rotaviru
dxuntreat
anim
inhibit
dx
heal
process
intestin
rotaviru
infect
may
howev
explain
observ
clinic
symptom
persist
viru
excret
ceas
clinic
outcom
challeng
rotavirusimmun
calv
unaffect
dx
treatment
contrast
exacerb
clinic
sign
dx
treatment
rotavirusna
calv
surprisingli
clinic
normal
dxuntreat
rotavirusimmun
calv
group
c
pattern
viru
excret
similar
clinicallyaffect
dxuntreat
rotavirusna
calv
group
howev
unclon
challeng
viru
known
mixtur
ofrotavirus
dh
pocock
person
commun
whose
individu
antigen
pathogen
known
rotavirus
multipli
without
caus
diseas
describ
bridger
pocock
bridger
oldham
excret
viru
could
repres
viru
rotaviru
excret
dxtreat
calv
challeng
howev
contrast
dxuntreat
calv
crouch
et
al
postul
role
cellmedi
mechan
releas
coronaviru
particl
infect
enterocyt
similar
mechan
may
involv
rotaviru
infect
serum
faecal
antibodi
respons
dxuntreat
calv
similar
report
rotaviru
previous
van
zaan
et
al
saif
suppress
serum
antibodi
respons
dx
treatment
antigen
exposur
ie
rotaviru
infect
agreement
work
other
thoma
et
al
pruett
et
al
result
demonstr
parenter
dx
treatment
suppress
mucos
well
system
antibodi
respons
antibodi
respons
serum
faec
complet
abolish
delay
depress
reason
alter
kinet
antibodi
product
dxtreat
calv
unclear
due
inhibitori
effect
viru
growth
dx
time
gc
administr
relat
exposur
antigen
affect
antibodi
respons
dx
treatment
start
prior
rotaviru
infect
antibodi
respons
markedli
suppress
wherea
dx
treatment
start
day
infect
effect
antibodi
product
agreement
other
report
vivo
administr
gc
time
exposur
nonrepl
antigen
suppress
system
antibodi
respons
cattl
pruett
et
al
suppress
antibodi
respons
rsv
requir
dx
treatment
start
prior
infect
thoma
et
al
studi
demonstr
immunosuppress
action
dx
antibodi
product
occur
earli
stage
initi
immun
respons
effect
plasma
cell
differenti
effect
gcinduc
suppress
differ
immunoglobulin
isotyp
report
butler
rossen
roth
et
al
find
howev
butler
rossen
look
preexist
serum
igm
igg
level
roth
et
al
measur
isotypespecif
antibodi
base
suggest
find
respons
brucella
abortu
affect
wherea
respons
ferritin
tetanu
toxin
present
studi
show
immun
respons
probabl
speed
recoveri
primari
rotaviru
infect
essenti
full
recoveri
antibodi
appear
role
resist
challeng
infect
exist
nonantibodymedi
immunopatholog
mechan
releas
viru
enterocyt
suggest
studi
need
identifi
precis
mechan
involv
recoveri
resist
rotaviru
infect
